Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05136196
Title field or adapter rule
{'original_value': 'Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:29.682634+00:00
Published At
2026-10-29T00:00:00+00:00
Record Updated At
2026-10-29
Source Retrieved At
2026-10-31T22:18:13.198083+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Melanoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Melanoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Unresectable Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-29", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT05136196"
protocolSection.identificationModule.officialTitle
"Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct
null

Study condition terms

  • Clinical Stage III Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Locally Recurrent Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Recurrent Laryngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Recurrent Oral Cavity Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Recurrent Oropharyngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Hypopharyngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Laryngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Melanoma (protocolSection.conditionsModule.conditions)
  • Metastatic Oral Cavity Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Oropharyngeal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Melanoma (protocolSection.conditionsModule.conditions)
  • Stage III Hypopharyngeal Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Laryngeal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Lip and Oral Cavity Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Hypopharyngeal Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Laryngeal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Lip and Oral Cavity Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Unresectable Melanoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Treatment (nivolumab and cabozantinib)'], 'description': 'Undergo tumor biopsies', 'name': 'Biopsy Procedure', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment (nivolumab and cabozantinib)'], 'description': 'Undergo collection of blood samples', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment (nivolumab and cabozantinib)'], 'description': 'Given PO', 'name': 'Cabozantinib S-malate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment (nivolumab and cabozantinib)'], 'description': 'Undergo CT scans', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment (nivolumab and cabozantinib)'], 'description': 'Undergo MRI scans', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment (nivolumab and cabozantinib)'], 'description': 'Given IV', 'name': 'Nivolumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • Cabozantinib S-malate (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.